Dipyridamole Induced Ischemia and Biomarkers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03688815|
Recruitment Status : Completed
First Posted : September 28, 2018
Last Update Posted : September 28, 2018
|Condition or disease||Intervention/treatment|
|Ischemic Heart Disease Ischemic Attack||Diagnostic Test: myocardial perfusion scintigraphy|
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Relationship Between the L-arginine Pathway Metabolites and Dipyridamole Stress Induced Transient Myocardial Ischaemia|
|Actual Study Start Date :||January 1, 2009|
|Actual Primary Completion Date :||January 1, 2010|
|Actual Study Completion Date :||January 1, 2017|
Patients with ischemic heart disease
Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
Diagnostic Test: myocardial perfusion scintigraphy
Myocardial perfusion scintigraphy as it is described in the international literature.
- Myocardial perfusion abnormality [ Time Frame: 5 year follow-up after MPS ]Myocardial perfusion was quantified based on myocardial perfusion scintigraphy (MPS).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03688815
|University of Pecs|
|Pécs, Baranya, Hungary, 7624|
|Principal Investigator:||Tihamer Molnar, MD||University of Pecs|